Growing Animal Cells for “Clean Meat”? Learnings from Biopharma
Time & Location
About the Event
Topics: 1) bioreactor types (flat plate, hollow fiber, microcarrier, suspension stirred tank, perfusion), 2) economics of cell production in current biopharma manufacturing, 3) strategies to reduce cost, 4) theoretical maximum limits on bioreactor productivity, 5) apoptosis control, 6) metabolite waste control, 7) CO2 inhibition, 8) Oxygen demand, 9) serum-free medium, 10) hydrolysate based medium, 11) thermal vs. filtration methods for medium sterilization, 12) engineering analysis of bioreactor scale limitations, 13) the shear damage myth, 14) control of bubble damage in bioreactors, 15) biosafety containment for animal cell culture, 16) biopharma microbial and viral contamination experience, 17) techno-economic analysis results, 18) structured self-assembly of "meat" from cultured cells, 19) roadmap of required further research, 20) discussion of challenges and opportunities.
About the Presenter: Brian Maiorella is Adjunct Professor of Chemical and Biomolecular Engineering, teaching bioprocess engineering and pharmaceutical product development at the University of California at Berkeley. Professor Maiorella retired from industry where he was vice president of process development at Chiron, a biopharmaceutical company with revenues of $1billion/yr from vaccines, neurologic and anti-cancer drugs developed using recombinant DNA technology. Dr. Maiorella began his career in the early 1980’s, a time when the recombinant DNA moratorium had just ended and animal cell culture for the production of biotherapeutics was just emerging. He is inventor on serum-free and protein-free cell culture media (both media based on chemically defined components and also media using hydrolysates). He is inventor on methods to address the impact of metabolic waste products that accumulate and inhibit further growth in cell culture, and on the design of bioreactors for oxygen and CO2 gas transport. He played a role on an early industry-wide consortium prioritizing research needs to support large scale animal cell culture to enable biotherapeutics production, including research to understand how shear and other hydrodynamic forces might impact cells in bioreactors. He has designed cell culture production facilities and has experience with production of biotherapeutics for human injection using hollow-fiber, perfusion, and fed-batch cell culture methods.